<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01509534</url>
  </required_header>
  <id_info>
    <org_study_id>GIMSI-001-2011</org_study_id>
    <nct_id>NCT01509534</nct_id>
  </id_info>
  <brief_title>Guideline-based Pacing Therapy for Reflex Syncope</brief_title>
  <acronym>SUP2</acronym>
  <official_title>Guideline-based Pacing Therapy for Reflex Syncope</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Multidisciplinare per lo Studio della Sincope</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Multidisciplinare per lo Studio della Sincope</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis: Dual-chamber pacemaker therapy with rate-hysteresis features is effective&#xD;
      in preventing syncopal recurrences in patients affected by cardioinhibitory (CI) forms of&#xD;
      reflex syncope diagnosed by means of carotid sinus massage, tilt table testing or implantable&#xD;
      loop recorder (ILR). The outcome is measured either by the time to first syncopal recurrence&#xD;
      or the total syncope burden.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Divergence of opinion exists regarding the efficacy of cardiac pacing in patients&#xD;
      affected by different forms of reflex syncope.&#xD;
&#xD;
      Definitions.&#xD;
&#xD;
      Severe syncope is defined when:&#xD;
&#xD;
        -  it is perceived by patient that it alters his/her quality of life, and&#xD;
&#xD;
        -  is unpredictable because occurs without, or with very short prodromes &lt; 10 sec (thus&#xD;
           exposing patients to risk of trauma) or, if preceded by prodromes, syncope recurs&#xD;
           despite appropriate therapies (CPM or drugs).&#xD;
&#xD;
      Recurrent syncopes: at least 2 episodes during the last year (including the index episode) or&#xD;
      3 episodes during the last 2 years (including the index episode).&#xD;
&#xD;
      Suspected (undetermined) reflex syncope: the suspicion of reflex syncope is based on a&#xD;
      history of uncertain syncope in the absence of (i) severe structural heart disease,&#xD;
      significant ECG abnormalities, or rhythm disturbances; (ii) orthostatic hypotension; and&#xD;
      (iii) non-syncopal causes of transient loss of consciousness.&#xD;
&#xD;
      Study protocol&#xD;
&#xD;
        1. The eligible patients undergo firstly carotid sinus massage (according to the method of&#xD;
           symptoms); if a diagnosis of cardioinhibitory carotid sinus syndrome (CI-CSS) is made, a&#xD;
           pacemaker is implanted and follow-up immediately starts.&#xD;
&#xD;
        2. If the carotid sinus massage is negative or vasodepressor, the patients undergo tilt&#xD;
           table testing (with nitroglycerin or clomipramine drug challenge); if a diagnosis of&#xD;
           VASIS 2B form is made, a pacemaker is implanted and follow-up immediately starts.&#xD;
&#xD;
        3. If tilt table testing is negative or a form different from VASIS 2B is induced, the&#xD;
           patients undergo ILR implantation. If a diagnosis of asystolic reflex syncope is made, a&#xD;
           pacemaker is implanted and follow-up immediately starts.&#xD;
&#xD;
      End-points End-point of the study is syncope recurrence after pacemaker (PM) implantation.&#xD;
      Syncope is defined as complete transient loss of consciousness. Pre-syncope is counted but it&#xD;
      is not an end-point.&#xD;
&#xD;
      Primary end-points:&#xD;
&#xD;
        1. Comparison of the time to first syncopal recurrence in CI-CSS and CI-TTT pts with PM and&#xD;
           in control patients with ILR.&#xD;
&#xD;
        2. Intra-patient comparison of the syncope burden in the year before and in the year&#xD;
           following PM implant in all patients receiving a PM (CCS, TTT and ILR groups). Index&#xD;
           syncope is not counted.&#xD;
&#xD;
      Follow-up One year after PM implantation for all enrolled patients for burden of syncope&#xD;
      end-points Until the study end for time to first syncope recurrence end-points. Thus, the&#xD;
      study ends one year after the enrollment of the last patient.&#xD;
&#xD;
      Study size Based on the sample size calculation the study will stop when 700 patients are&#xD;
      enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>syncope recurrence after PM implantation</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>syncope burden after PM implantation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">281</enrollment>
  <condition>Syncope</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by reflex syncopes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients affected by severe, recurrent, certain or suspected (undetermined) reflex&#xD;
             syncopes, aged â‰¥ 40 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reflex syncopes due to reversible causes, e.g., vasoactive drugs, concomitant&#xD;
             diseases, etc&#xD;
&#xD;
          -  Suspected of certain cardiac syncope&#xD;
&#xD;
          -  Syncope caused by orthostatic hypotension&#xD;
&#xD;
          -  Non-syncopal causes of transient loss of consciousness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Brignole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedali del Tigullio, Lavagna, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale Generale Regionale</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO di Rilievo Nazionale e di Alta Specializzazione Garibaldi</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO S. Giuseppe</name>
      <address>
        <city>Empoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale S. Giovanni di Dio</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Ospedali del Tigullio</name>
      <address>
        <city>Lavagna</city>
        <zip>16033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Annunziata</name>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pacemaker</keyword>
  <keyword>implantable loop recorder</keyword>
  <keyword>syncope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Syncope, Vasovagal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

